The effectiveness of adding famotidine and vitamin B6 to standard drug treatment in patients with schizophrenia disorder

Investigating the effectiveness of adding famotidine and vitamin B6 to standard drug treatment in reducing negative symptoms in patients with schizophrenia disorder: a clinical trial with a control group

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150822023705N16

Enrollment

Registered

2023-04-17

Start date

2023-05-10

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: The group will receive the combination of famotidine/vitamin B6 pills in three months. The daily dose will be 1 pill of 190 mg (famotidine, 40 mg and vitamin B6, 15

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Schizophrenia Disorder diagnoses with negative symptoms according to Diagnostic and Statistical Manual of Mental Disorders fifth edition by a psychiatrist under treatment with aripiprazole

Exclusion criteria

Exclusion criteria: Disagreement to participate in the study

Design outcomes

Primary

Measure	Time frame
Severity of negative symptoms. Timepoint: before intervention- 6 weeks later- 12 weeks late. Method of measurement: Positive and Negative Symptom Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShakiba Salmani

Kermanshah University of Medical Sciences

shakiba.salmani@yahoo.com+98 83 3826 4513

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026